Spermatogenesis‐associated 19 (SPATA 19) is a cancer/testis antigen overexpressed in
various cancers. However, its protein expression profile in malignant or non‐malignant …

The androgen-dependent or-independent pathways are regarded as primary therapeutic
targets for the neoplasm of the prostate. Mucosa-associated lymphoid tissue 1 (MALT1) …

Genomic instability is one of the hallmarks of tumors that contributes to tumor heterogeneity
and drug resistance. Genetically targeted cancer therapy that focused on genome instability …

Background New biomarkers of progression in patients with prostate cancer (PCa) are
needed to improve their classification and clinical management. This systematic review …

Purpose The aberrant expression of casein kinase 2 (CK2) has been reported to be involved
in the tumorigenesis and progression of prostate cancer. The inhibition of CK2 activity …

Background: Progesterone receptor (PR) is a critical regulator in reproductive tissues that
controls a variety of cellular processes. The objective of the study was to study the PR …

Androgen receptor signaling inhibitors (ARSi) are a mainstay for patients with metastatic
castration-resistant prostate cancer (mCRPC). However, patient response is heterogeneous …

Abstract In the United States, prostate cancer (PCa) is the most commonly diagnosed cancer
in males. For PCa at the late hormone-refractory stage, substantial improvement in treatment …

Uneven replication creates artifacts during whole genome amplification (WGA) that
confound molecular karyotype assignment in single cells. Here, we present an improved …

Oxidative stresses that govern different cellular activities including activities of inflammatory
processes play a critical role in the development of prostate cancer (PCa). PCa is …